The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Clozapine,'' for the orally disintegrating tablets (ODTs). The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for clozapine ODTs.
Document
Bioequivalence Recommendations for Clozapine Orally Disintegrating Tablets/Oral; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Clozapine,'' for the orally ...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
80 FR 26063
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Bioequivalence Recommendations for Clozapine Orally Disintegrating Tablets/Oral; Draft Guidance for Industry; Availability,” thefederalregister.org (May 6, 2015), https://thefederalregister.org/documents/2015-10478/bioequivalence-recommendations-for-clozapine-orally-disintegrating-tablets-oral-draft-guidance-for-industry-availability.